EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 <50%

被引：0
|
作者：
Rizvi, N. [1 ]
Lee, S. [2 ]
Curtis, P. [2 ]
Caldwell, W. [2 ]
Gao, B. [2 ]
Rietschel, P. [2 ]
机构：
[1] Columbia Univ, Med Ctr, New York, NY USA
[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
Anti-PD-1; cemiplimab; REGN2810;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.04-26
引用
收藏
页码：S931 / S932
页数：2
相关论文
共 50 条
  • [31] Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
    Makharadze, Tamta
    Gogishvili, Miranda
    Melkadze, Tamar
    Baramidze, Ana
    Giorgadze, Davit
    Penkov, Konstantin
    Laktionov, Konstantin
    Nemsadze, Gia
    Nechaeva, Marina
    Rozhkova, Irina
    Kalinka, Ewa
    Li, Siyu
    Li, Yuntong
    Kaul, Manika
    Quek, Ruben G. W.
    Poulio, Jean-Francois
    Seebach, Frank
    Lowy, Israel
    Gullo, Giuseppe
    Rietschel, Petra
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (06) : 755 - 768
  • [32] Flexibility in chemotherapy regimens in first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with cemiplimab in combination with chemotherapy: analysis from EMPOWER-Lung 3
    Rosen, Jan-Paul
    Makharadze, Tamta
    Gogishvili, Miranda
    Melkadze, Tamar
    Baramidze, Ana
    Zhu, Cong
    Mcintyre, Debra Ag
    Venkateshan, Satish
    Kim, Eric
    Magnan, Heather
    Pouliot, Jean -Francois
    LUNG CANCER, 2025, 200
  • [33] Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%
    Wang, Liting
    Peng, Ye
    Zeng, Xiaohui
    Peng, Liubao
    Li, Sini
    Qin, Shuxia
    Wan, Xiaomin
    Tan, Chongqing
    ADVANCES IN THERAPY, 2021, 38 (08) : 4354 - 4365
  • [34] Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%
    Liting Wang
    Ye Peng
    Xiaohui Zeng
    Liubao Peng
    Sini Li
    Shuxia Qin
    Xiaomin Wan
    Chongqing Tan
    Advances in Therapy, 2021, 38 : 4354 - 4365
  • [35] PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC: A Cost-Effectiveness Analysis in China
    Liu, Qiao
    Luo, Xia
    Zhou, Zhen
    Peng, Liubao
    Yi, Lidan
    Wan, Xiaomin
    Tan, Chongqing
    Zeng, Xiaohui
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [36] EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients ( pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%-3-year update
    Kilickap, S.
    Ozguroglu, M.
    Sezer, A.
    Gumus, M.
    Bondarenko, I.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O. A.
    Clingan, P.
    Sriuranpong, V.
    He, X.
    Pouliot, J-F.
    Seebach, F.
    Lowy, I.
    Gullo, G.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S42 - S43
  • [37] Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
    Kilickap, S.
    Sezer, A.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Li, S.
    Lee, S.
    Makharadze, T.
    Paydas, S.
    Nechaeva, M.
    Seebach, F.
    Weinreich, D. M.
    Yancopoulos, G. D.
    Gullo, G.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S101 - S101
  • [38] Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer
    Feliciano, Josephine Louella
    McLoone, Dylan
    Xu, Yingxin
    Quek, Ruben G. W.
    Kuznik, Andreas
    Pouliot, Jean-Francois
    Gullo, Giuseppe
    Rietschel, Petra
    Guyot, Patricia
    Konidaris, Gerasimos
    Chan, Keith
    Keeping, Sam
    Wilson, Florence R.
    Freemantle, Nick
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [39] First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial (vol 24, pg 989, 2023)
    Ozguroghu, M.
    Kilickap, S.
    Sezer, A.
    LANCET ONCOLOGY, 2023, 24 (10): : e405 - e405
  • [40] PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
    Lo Russo, Giuseppe
    Prelaj, Arsela
    Dolezal, James
    Beninato, Teresa
    Agnelli, Luca
    Triulzi, Tiziana
    Fabbri, Alessandra
    Lorenzini, Daniele
    Ferrara, Roberto
    Brambilla, Marta
    Occhipinti, Mario
    Mazzeo, Laura
    Provenzano, Leonardo
    Spagnoletti, Andrea
    Viscardi, Giuseppe
    Sgambelluri, Francesco
    Brich, Silvia
    Miskovic, Vanja
    Pedrocchi, Alessandra Laura Giulia
    Trovo', Francesco
    Manglaviti, Sara
    Giani, Claudia
    Ambrosini, Paolo
    Leporati, Rita
    Franza, Andrea
    Mcculloch, John
    Torelli, Tommaso
    Anichini, Andrea
    Mortarini, Roberta
    Trinchieri, Giorgio
    Pruneri, Giancarlo
    Torri, Valter
    De Braud, Filippo
    Proto, Claudia
    Ganzinelli, Monica
    Garassino, Marina Chiara
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (06)
12345